Clinical Trial Update: Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 clinical trial assessing safety, disease progression and cellular kinetics of YTB323 in participants with non-active progressive multiple s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• YTB323

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Progressive Multiple Sclerosis | Phase 1, Phase 2 | Status: RECRUITING